quently with time after onset of ischemia, but may oc cur as little as 2 hours') or even within 90 minutes of ischemic onset.') Our previous study found that there is a good correlation between the occurrence of hemorrhagic transformation and reduction of the residual cerebral blood flow (CBF) in the ischemic region.") In brief, the risk of hemorrhagic transfor mation after recanalization of occluded vessels by local intra-arterial thrombolytic therapy in patients treated within 6 hours of onset was higher when the ratio of ischemic regional activity to ipsilateral cerebellar activity calculated by pretherapeutic tech netium-99m-labeled hexamethylpropyleneamine oxime single photon emission computed tomogra phy (SPECT) was less than 0.35.
The present study examined several markers for the coagulation and fibrinolytic systems before and after local intra-arterial thrombolytic therapy to evaluate whether responses of the coagulation and fibrinolytic systems are another risk factor for hemor rhagic transformation.
Subjects and Methods
This study included 34 patients, 17 males and 17 females aged 35 to 83 years (mean ± SD 68 ± 8 yrs), with acute cerebral infarction admitted to our hospital between September, 1989 and May, 1992. Acute ischemic stroke was classified into cardioem bolic infarction and atherothrombotic infarction ac cording to the guidelines of the Cerebral Embolism Task Force 2) on the basis of the onset pattern, angiographic findings, and the results of cardio vascular examinations such as electrocardiography, echocardiography, and Holter electrocardiography. Local intra-arterial thrombolytic therapy was per formed using UK (24 patients) or t-PA (10 patients) according to our three criteria: 1) no apparent hypo density areas observed on computed tomography (CT) scans on admission; 2) the patient could be treated within 6 hours, in principle, of onset; and 3) affected arteries indicated by the symptoms were demonstrated to be occluded by cerebral angiogra phy. Informed consent was obtained from the pa tient or relatives.
The pretherapeutic CBF was evaluated in the ter ritory of occluded vessels by SPECT. Cerebral digital subtraction angiography was performed by the Seldinger method using a 5-F catheter by placing a 6-F sheath in the right or left femoral artery. The occluded vessel was identified, and the tip of a Tracker-18 catheter (Target Therapeutics, Los Angeles, Cal., U.S.A.) was advanced into the throm bus, or upstream or downstream from the occlusion site. UK (240,000 U; Wakamoto Pharmaceutical Co., Ltd., Tokyo) or t-PA (8 mg; Silteplase; Dai-ichi Pharmaceutical Co., Ltd., Tokyo) was dissolved in physiological saline (20 ml) and injected manually over about 10 minutes. Angiography was performed immediately after each infusion, which was repeated until recanalization of the occluded vessel was con firmed. The maximum dose of the thrombolytic agents was 1,200,000 U UK or 32 mg t-PA. t-PA was mostly used after April, 1991. Recanalization of the vessel was considered "complete" when the blood flow was clearly re-established regardless of atheromatous plaque left at the occluded site, "par tial" when the blood flow was partially restored but dispersed embolus occluded more distal vessels or when a major artery with multiple occlusions was partly recanalized, and "none" when no reperfusion was observed. The patients were given 10% glycerol (200 ml) or 20% mannitol (300 ml) before the therapy, and intravenous heparin (5000 U) and drip infusion of micromolecular dextran (500 ml) during the therapy.
Blood coagulation and fibrinolytic system in dicators were measured in arterial blood obtained through a short 6-F sheath placed in the right or left femoral artery before and immediately after the thrombolytic therapy, and in venous blood from the arm at 1, 24, and 48 hours after the therapy. Fibrinogen-fibrin degradation products (FDP) (nor mal range < 10 mg/dl), fibrinogen (normal range 200-400 mg/dl), and a2-plasmin inhibitor (a2-PI) (normal range 80-130%) were assayed by latex ag glutination, sodium sulfite precipitation, and chromogenic substrate S-2251 (Kabi Diagnostica, Stockholm, Sweden), respectively. Plasmin-a2 plasmin inhibitor complex (PIC) (normal range < 0.8 mg/dl), thrombin-antithrombin III complex (TAT) (normal range < 3.0 ,ug/l), and D-dimer (nor mal range < 150 ng/ml) were measured by enzyme linked immunosorbent assay. CT was performed immediately after the therapy, on the next day, and at 1 week, 2 weeks, and 1 month after the therapy in all patients. The patients were classified based on the CT findings into nonhemor rhagic and hemorrhagic transformation groups. The patients treated with UK in the nonhemorrhagic group were further classified into three subgroups: 1) patients treated with 480,000 U or less, 2) those treated with 720,000 U, and 3) those treated with 960,000 U or more. The small number of patients treated with t-PA were not subdivided. Recanaliza tion in the nonhemorrhagic group patients treated with UK was classified as complete, partial, or none, and in those treated with t-PA as complete or partial, to evaluate D-dimer as an indicator for recanaliza tion. : UK (n = 4) or t-PA (n = 3 immediately and 1 hour after therapy compared to each dose subgroup of patients without hemorrhagic transformation. The FDP levels in patients treated with 960,000 U or more significantly increased im mediately and 1 hour after the therapy, although not as much as in patients with hemorrhagic transforma tion, compared with the pretreatment levels. The values in each dose subgroup returned to the pretreat ment levels within 24 hours of the therapy (Fig. 1 up   per ). In the t-PA group, the FDP levels in all patients rose slightly above the pretreatment levels, then returned to near the pretreatment levels 1 hour after the therapy and were within the normal range at 48 hours (Fig. 1 lower) . In the UK group, the fibrinogen levels decreased in the patients treated with 960,000 U or more until 48 hours after the therapy. However, there were no Neurol Med Chir (Tokyo) 35, March, 1995 significant differences between the hemorrhagic transformation group and the various nonhemor rhagic subgroups (Fig. 2 upper) . In the t-PA group, no significant reduction of fibrinogen level was seen in either hemorrhagic transformation or nonhemor rhagic group (Fig. 2 lower) .
In all patients in the UK group, the a2-PI activities significantly decreased immediately and 1 hour after the therapy. The values returned to 50% or 60% of pretreatment activities 24 hours later, and were still lower than the normal range at 48 hours. There were no differences in the values between the hemorrhagic transformation group and the nonhemorrhagic group (Fig. 3 upper) . In the t-PA group, the a2-PI ac tivities significantly decreased immediately after the therapy. However, the values began to rise at 1 hour, and returned to the pretreatment levels within 24-48 hours of the therapy (Fig. 3 lower) . In all patients in the UK group, the PIC levels significantly increased immediately after the therapy and returned to the pretreatment levels at 24 hours. There were no differences between the hemorrhagic transformation group and the various nonhemor rhagic subgroups (Fig. 4 upper) . In the t-PA group, the PIC levels in the hemorrhagic transformation group and the nonhemorrhagic group also significant ly increased immediately and 1 hour after the therapy.
Furthermore, there were significant differences between these groups. The values in both groups returned to the pretreatment levels by 24 hours after the therapy (Fig. 4 lower) . Fig. 4 PIC levels in patients with (closed circle) and without hemorrhagic transformation (open symbols) after thrombolytic therapy (upper: UK group, lower: t-PA group). 0: <_48 104 U UK (n = 8) or t-PA (n = 7), A: 72 x 104 U UK (n = 4), o : >_ 96 x 104 U UK (n = 5),,: UK (n = 2) or t-PA (n = 3). *Significant difference from the pretreatment value (p < 0.05). #Significant difference between two groups (p < 0.05). : UK (n = 2) or t-PA (n = 3).
The UK and t-PA groups showed no significant elevation of the TAT level after the therapy, com pared with the pretreatment levels. However, the values in most patients were higher than the normal range before and after the therapy (Fig. 5) .
The D-dimer levels in both the UK and t-PA groups showed a tendency to increase until 1 or 24 hours after the therapy. There was a significant difference in the values between the hemorrhagic transformation group and the nonhemorrhagic group, at 24 hours after the therapy in the UK group, and at 24 and 48 hours after the therapy in the t-PA group (Fig. 6A, B) . In the nonhemorrhagic group treated with UK, the D-dimer levels in patients with complete recanalization was higher than that in pa tients with partial and no recanalization 1 hour after the therapy. In the nonhemorrhagic group treated with t-PA, the values in the patients with complete recanalization was also high, immediately and 1 hour after the therapy, compared with that in the patients 
